²²⁵Actinium-armed antibody targeting CCR8⁺ regulatory T cells synergizes with immunotherapy to promote tumor rejection in syngeneic colorectal cancer models.

ABSTRACT:

Background

Colorectal cancer (CRC) remains a formidable threat to health worldwide. Immunotherapy with immune checkpoint inhibitors results in only a minority of CRC patients experiencing long-term progression-free survival, at the expense of significant autoimmune toxicity. Development of new therapeutics to "wake up" the immune system to fight CRC is necessary. Here we investigated for the first time radioimmunotherapy (RIT) directed towards CCR8, a marker of tumor-infiltrating immunosuppressive T-regulatory cells (ti-Tregs) as a method to recover anti-tumor immunity followed by immunotherapy in CRC models.

Methods

225Actinium (²²⁵Ac)-labeled anti-CCR8 antibody and anti-CTLA-4 immunotherapy were used to assess their potential synergistic effects in syngeneic mur

SUBMITTER: Frank C 

PROVIDER: S-EPMC12479553 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature